IL6 and demyelinating disease: Studies have investigated the possible usefulness of IL-6 as a biomarker of CNS diseases, especially in the context of demyelinating diseases; however, the small size of the studied samples and the inclusion of restricted neurological conditions limit its usefulness in clinical practice.